2-Benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
First Claim
Patent Images
1. ) A compound of formula (I), wherein R1, R2 which may be identical or different, denote a group selected from among optionally substituted C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, C3-C8-heterocycloalkyl, —
- X-aryl, —
X-heteroaryl, —
X-cycloalkyl, —
X-heterocycloalkyl, —
NR8-aryl, —
NR8-heteroaryl, —
NR8-cycloalkyl, and —
NR8-heterocycloalkyl, or a group selected from among hydrogen, halogen, COXR8, CON(R8)2, COR8 and XR8, or R1 and R2 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms, R3 denotes hydrogen or a group selected from among optionally substituted C1-C12-alkyl, C2-C12-alkenyl, C2-C12-alkynyl, aryl, heteroaryl, C3-C12-cycloalkyl, C3-C12-cycloalkenyl, C7-C12-polycycloalkyl, C7-C12-polycycloalkenyl and C5-C12-spirocycloalkyl or R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 to 2 heteroatoms, R4 denotes optionally substituted aryl or heteroaryl, R5 denotes a group selected from among hydrogen, CHO, XH, —
X—
C1-C2-alkyl and an optionally substituted C1-C3-alkyl group, R6 denotes a group selected from among hydrogen, NH2, XH, halogen and a C1-C3-alkyl group optionally substituted by one or more halogen atoms, R7 denotes hydrogen or —
CO—
C1-C4-alkyl, —
CO—
NH—
C1-C4-alkyl, —
CO—
X—
C1-C4-alkyl, and X in each case independently of one another denote O or S, R8 in each case independently of one another denote hydrogen or a group selected from among optionally substituted C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, benzyl and phenyl, R10 and R11 in each case independently of one another denote hydrogen or a group selected from among optionally substituted C1-C4-alkyl, or R10 and R11 together denote a 2-5 membered alkyl bridge, or the pharmacologically acceptable acid addition salt, solvate or hydrate thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to new 2-benzylaminodihydropteridinones of general formula (I)
wherein the groups R1 to R7, R10 and R11 have the meanings given in the claims and specification, the isomers thereof, methods of preparing these dihydropteridinones and their use as medicaments.
-
Citations
9 Claims
-
1. ) A compound of formula (I),
wherein R1, R2 which may be identical or different, denote a group selected from among optionally substituted C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, C3-C8-heterocycloalkyl, — - X-aryl, —
X-heteroaryl, —
X-cycloalkyl, —
X-heterocycloalkyl, —
NR8-aryl, —
NR8-heteroaryl, —
NR8-cycloalkyl, and —
NR8-heterocycloalkyl, ora group selected from among hydrogen, halogen, COXR8, CON(R8)2, COR8 and XR8, or R1 and R2 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms, R3 denotes hydrogen or a group selected from among optionally substituted C1-C12-alkyl, C2-C12-alkenyl, C2-C12-alkynyl, aryl, heteroaryl, C3-C12-cycloalkyl, C3-C12-cycloalkenyl, C7-C12-polycycloalkyl, C7-C12-polycycloalkenyl and C5-C12-spirocycloalkyl or R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 to 2 heteroatoms, R4 denotes optionally substituted aryl or heteroaryl, R5 denotes a group selected from among hydrogen, CHO, XH, —
X—
C1-C2-alkyl and an optionally substituted C1-C3-alkyl group,R6 denotes a group selected from among hydrogen, NH2, XH, halogen and a C1-C3-alkyl group optionally substituted by one or more halogen atoms, R7 denotes hydrogen or —
CO—
C1-C4-alkyl, —
CO—
NH—
C1-C4-alkyl, —
CO—
X—
C1-C4-alkyl, andX in each case independently of one another denote O or S, R8 in each case independently of one another denote hydrogen or a group selected from among optionally substituted C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, benzyl and phenyl, R10 and R11 in each case independently of one another denote hydrogen or a group selected from among optionally substituted C1-C4-alkyl, or R10 and R11 together denote a 2-5 membered alkyl bridge, or the pharmacologically acceptable acid addition salt, solvate or hydrate thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
- X-aryl, —
Specification